@prefix : <http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl> .

<http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl> rdf:type owl:Ontology ;
                                                                                                    owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                                                    rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/272398"^^xsd:anyURI ;
                                                                                                    rdfs:label "Artemether/Lumefantrine and Stevens-Johnson syndrome: a recommendation for continued vigilance in malaria-endemic areas"^^rdfs:Literal ;
                                                                                                    owl:versionInfo "draft-v0.95-20210510"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedByData
mp:supportedByData rdf:type owl:ObjectProperty .


#################################################################
#    Classes
#################################################################

###  http://www.w3.org/ns/prov#Organization
<http://www.w3.org/ns/prov#Organization> rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ALU
:ALU rdf:type owl:NamedIndividual ,
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Malaria ;
     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "P01BF01 " ;
     rdfs:label "ALU" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#AcetylsalicylicAcid
:AcetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BA01 " ;
                     rdfs:label "acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Acknowledment
:Acknowledment rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Professor Ambrose Isah, Nigeria and Daniele Sartori, Uppsala Monitoring 
Centre for valuable input.""" ;
               rdfs:label "Acknowledment" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Addendum_regarding_similar_anti-malaria__drugs
:Addendum_regarding_similar_anti-malaria__drugs rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In VigiBase there is one report on the combination Artemether-SJS from Kenya, one report on ALU-TEN from India and one report on Artemether-TEN from France. Regarding other artemisinin class drugs or combinations, VigiBase contained 10 reports of SJS and 4 of TEN. The observed number did not exceed the statistically expected for any of the combinations. 10 of the 14 reports were related to the use of artesunate and present a picture similar to the described for ALU, i.e. sparse information, predominately short times to onset and several co-suspect concomitant drugs. Neither rash nor more severe (systemic) skin reactions appear to be labelled for artesunate." ;
                                                rdfs:label "Addendum regarding similar anti-malaria  drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Albendazole
:Albendazole rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "P02CA03" ;
             rdfs:label "albendazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Angioedema
:Angioedema rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T78.3XXA" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10002424 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Angioedema" ;
            rdfs:label "angioedema" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Artemisinin_and_derivatives
:Artemisinin_and_derivatives rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "P01BE" ;
                             rdfs:label "Artemisinin and derivatives" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Discussion
:Discussion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Discussion> ;
            mp:references :Ref.8 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "At the time of data retrieval there were 19 reports of SJS in relation to ALU treatment in VigiBase. The US labelling mentions serious skin reactions (bullous eruption) in the post marketing experience.8 As prodromal symptoms of SJS are fever, headache, sore throat and fatigue, there are alternative explanations to the association between ALU and SJS. An early stage SJS caused by another factor could be mistaken for malaria and treated as such or the malarial disease could be causing the SJS. The short TTO of 0-2 days in most of the reported cases is somewhat atypical and does weaken the suspicion of a causal association between the drug and the reaction while not excluding it. The insidious start of SJS further makes an exact onset of the condition difficult to establish. There is limited information in the described cases on their respective diagnostic certainty of malaria. The presence of paracetamol, NSAIDs or ASA as concomitant treatment in malaria or SJS would be expected but obviously also obscures any causality assessment. Since case descriptions and information are sparse, other potential but unaccounted-for causes of the SJS appearing within a reasonable timeframe are not possible to rule out, e.g. other infections and other drugs or traditional remedies used." ;
            rdfs:label "Discussion" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Dose_of_ALU
:Dose_of_ALU rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
             mp:references :Ref.2 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A typical treatment course would be six doses consisting of 1-4 tablets per dose over three days ." ;
             rdfs:label "Dose of ALU" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Dr_Birgitta_Grundmark
:Dr_Birgitta_Grundmark rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Upsalla Monitoring Centre" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Birgitta" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Grundmark" ;
                       rdfs:label "Dr. Birgitta Grundmark" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#FaceEdema
:FaceEdema rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R60.9" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10016029 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Face oedema" ;
           rdfs:label "face edema" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Indian_labelling
:Indian_labelling rdf:type owl:NamedIndividual ,
                           <http://purl.obolibrary.org/obo/OAE_0001197> ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Angioedema ,
                                                                                           :Pruritus ,
                                                                                           :Rash ,
                                                                                           :Urticaria ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
                  mp:references :Ref.7 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "An example of an Indian package insert (Lumerax®) includes rash, pruritus, urticaria, and angioedema.7" ;
                  rdfs:label "Indian labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.2 ,
                                        :Ref.7 ,
                                        :Ref.8 ,
                                        :Ref.9 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "United Kingdom, Australian and Swiss labels (Riamet®) are very similar and include as acknowledged adverse reactions of the drug combination: rash, urticaria and hypersensitivity, the latter without any further specification.2 Angioedema and face edema are mentioned as reported from post marketing experience. An example of an Indian package insert (Lumerax®) includes rash, pruritus, urticaria, and angioedema.7 The United States Food and Drug Administration (US FDA) label (Coartem®) mentions the following regarding the post marketing experience: “hypersensitivity reactions: like […] serious skin reactions (bullous eruption) have been reported”. This could evidently encompass SJS while SJS is not included per se in the labelling.8 In an article describing an ADR reporting survey performed in Uganda one case is described as reported from a doctor where a “52 year old female on Coartem oral route developed sores on the whole body”. No further information is available on the case which can be suspected of describing SJS or TEN.9" ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Malaria
:Malaria rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "B52.9" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10025487 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Malaria" ;
         rdfs:label "malaria" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#NSAIDs
:NSAIDs rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01A" ;
        rdfs:label "NSAIDs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Novartis_response
:Novartis_response rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Response_to_Pharmacovigilance_Signal_Report> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_pharmacovigilance_signal_report> <http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Artemether/Lumefantrine_and_Stevens-Johnson_syndrome:_a_recommendation_for_continued_vigilance_in_malaria-endemic_areas> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Response from Novartis
Property of Novartis
Confidential

Introduction 
This document provides Novartis’ comment on the draft of “Artemether/Lumefantrine and StevensJohnson syndrome: continued prospective pharmacovigilance suggested” which will be published in Signal from UMC – WHO Collaborating Centre for International Drug Monitoring. The draft report concludes: “The US labelling mentions serious bullous skin reactions which could potentially include cases of SJS. The VigiBase case series gives suspicion of a causal association between ALU and SJS although some arguments against such an association are also present within it. While a firm conclusion on causality cannot be drawn at this point, national centres should be aware of this potential issue, monitor and be prepared to take precautionary steps nationally if considered necessary.” 


Background 
Coartem/Riamet (artemether/lumefantrine) was first registered in 1998 and Novartis Pharma is currently the MAH in over 67 countries. The combined cumulative exposure for all formulations of Coartem/Riamet is estimated to be over 970 million patients (8 million PTY). Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are being closely monitored in the Coartem/Riamet PSURs as potential risk. In the last PSUR (01 Nov 2013 – 01 Oct 2016) assessment Report, the Pharmacovigilance Risk Assessment Committee (PRAC) agreed with the company’s assessment that no label change is warranted and monitoring of the topic should continue. The Coartem USPI mentions under Postmarketing Experience serious skin reactions (bullous eruption), also stating that due to the voluntary reporting it is not always possible to establish a causal relationship to drug exposure. It should be noted that, there are several generic formulations of artemether (synthetic and natural)-lumefantrine combinations on the market, including substandard or counterfeit medications. 
Epidemiology SJS and TEN are rare but life-threatening mucocutaneous diseases [Harr T et al., 2010]. Several drugs are associated with an increased risk of SJS/TEN including antiepileptics, antipsychotics, antimicrobials, antivirals, [Hirapara et al, 2017], allopurinol, analgesics like paracetamol [Khawaja et al 2012, Biswal et al, 2014], NSAIDs, COX-2 inhibitors, sertraline, [Roujeau et al., 1995; Mockenhaupt et al., 2008] and non-ACT antimalarials like sulfadoxine/pyrimethamine [Fansidar, PIL], atovaquone and proguanil HCl [Malarone, SmPC] and mefloquine HCl [Lariam, SmPC]. SJS and TEN are also reported to occur at a higher incidence in HIV-infected persons [Knight et al, 2014]. Reported incidence rates of SJS/TEN range from 1.4 to 12.7 cases per million person-years [Diphoorn et al., 2016; Rzany et al., 1996]. In a 1:4 matched case-control analysis Frey et al [Frey et al, 2017] found, that black and Asian patients were at a 2-fold risk of SJS/TEN when compared with white patients. This finding is particularly relevant because of the malaria endemic regions. Difficulties in obtaining definitive diagnoses of SJS and TEN are also a hurdle in estimating an accurate incidence [Yang et al 2016]. 
Methodology 
Novartis global safety database was searched cumulatively through 30th Sep 2017 with SMQ narrow scope “Severe cutaneous adverse reactions” with Coartem/Riamet. A literature review was also conducted based on searches in Medline, Embase and Biosis databases. 
Results 
Novartis safety database search A total of eight cases were retrieved from the Novartis global safety database [Angola (3), Cameroon (1), France (1), Kenya (2) and Malawi (1)]. All cases were reported by health care professionals. Of these 8 cases, one was a clinical trial case concerning a female child of unknown age. The event “bullous rash on the face and anterior trunk associated with fever and septicemia” with a fatal outcome was assessed as not suspected to be related to the study medication by the investigator. Among the remaining seven spontaneous reports, the relevant events reported were Stevens Johnson syndrome (n=5), Toxic epidermal necrolysis (n=1) and Toxic skin eruption (n=1); in three cases the events were reported with a fatal outcome. The age group distribution of these seven cases was as follows: two infants (19 months and 2 years), one child (7 years) and four adults (27, 36, 45 and 54 years). Three reports concerned females and four males. The time to onset calculated from the start of the Coartem/Riamet therapy was provided only in four cases and ranged from 2-7 days. In all of the cases medications which are strongly associated with risk of SJS/TEN were given concomitantly, like: phenobarbital, amoxicillin, paracetamol, sulfamethoxazole-trimethoprim, lopinavir, tenofovir and ritonavir (as part of HIV treatment), allopurinol, methyldopa, chloramphenicol, ibuprofen and captopril. In one of these cases, the concomitant medication (amoxicillin and paracetamol) was started on the same day as Coartem. In all of the remaining cases, the exact start and end dates for the comedications were not provided. In two cases with multiple co-medications, SJS was reported in the medical history with the possibility that the reported event occurred in the context of drug rechallenge. Some of the cases were also poorly documented with not much information provided for a proper assessment. Literature Cumulative review identified the below relevant publication: [Matthew O et al 2013], compared the treatment outcome among patients treated with artesunate/amodiaquine to those treated with artemether-lumefantrine for acute uncomplicated malaria. One case of Steven Johnson-like reaction was observed with artemether-lumefantrine in the study starting on the third day, after completion of therapy. This was adequately treated at the centre and no other complaint was received from the patient. Comment: No further details were provided about concomitant drugs and the authors have reported only SJS-like reaction. 
Discussion and Conclusion 
The review revealed that in all cases, there were alternative explanations in the form of additional suspect or concomitant medications which are strongly associated with the risk of severe skin reactions. Some cases contained limited information, which precluded adequate assessment. The reporting frequency with Coartem/Riamet is 0.01 case per million PTY that is far below the reported incidences in the general population (1.4 to 12.7 cases per million PTY) even when considering underreporting or ethnic differences. In conclusion, in line with the PRAC conclusions, Novartis believes that the current data does not warrant for a change of the relevant product information and will continue close monitoring the safety topic in the frame of the PSURs. 
References
1. Biswal S, Sahoo SS. Paracetamol induced Stevens-Johnson syndrome--toxic epidermal necrolysis overlap syndrome. Int J Dermatol. 2014 Aug; 53(8):1042-4. 
2. Diphoorn J, Cazzaniga S, Gamba C, Schröder J, Citterio A, Rivolta AL, et al. Incidence, causative factors and mortality rates of  Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry Pharmacoepidemiol Drug Saf, 25 (2016), pp. 196-203. 
3. Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. The Epidemiology of Stevens - Johnson syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol. 2017 Jun; 137(6):1240-1247. 
4. Fansidar tablets (500 mg sulfadoxine and 25 mg pyrimethamine) Australian label Roche Products Pty Limited, 2008. 
5. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39. 
6. Hirapara H N, Patel T K, Barvaliya M J, Tripathi C. Drug-induced Stevens–Johnson syndrome in Indian population: A multicentric retrospective analysis. Niger J Clin Pract [serial online] 2017 [cited 2017 Nov 3];20:978-83. 
7. Khawaja A, Shahab A, Hussain SA. Acetaminophen induced Steven Johnson syndrome-toxic epidermal necrolysis overlap.J Pak Med Assoc. 2012 May;62(5):524-7. 
8. Knight L, Muloiwa R, Dlamini S, Lehloenya RJ. Factors Associated with Increased Mortality in a Predominantly HIV-Infected Population with Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. Hoshino Y, ed. PLoS ONE. 2014;9(4):e93543. 
9. Lariam 250 mg Tablets - Summary of Product Characteristics. 2017. 
10.Malarone 250 mg/100 mg filmcoated tablets-Summary of Product Characteristics. 2016. 
11.Matthew O, Sunday JN, Emmanuel OI, E, et al. Comparative assessment of two artemisinin based combination therapies in the treatment of uncomplicated malaria among University students in Nigeria. International Journal of Drug Development and Research. 2013;5(2):211-221. 
12.Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008 Jan; 128(1):35-44. 
13.Roujeau, JC. et al. Medication use and the risk of Stevens-Johnson  syndrome or toxic epidermal necrolysis. N. Engl. J. Med.1995; 333, 1600-1607. 
14.Rzany, M. Mockenhaupt, S. Baur, W. Schröder, U. Stocker, J. Mueller, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996; 49, pp. 769-773. 
15.Yang M, Lee J, Kim J, Kim G, Kim B, Kim J, et al. Incidence of StevensJohnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance Database in Korea. PLoS One, 11 (11) (2016), p. e0165933.""" ;
                   rdfs:label "Novartis response" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#OverallReportsInVigibase
:OverallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Stevens-JohnsonSyndrome ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 19 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 11 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 5 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 64 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_median_age> "29.0"^^xsd:float ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 2 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Overall reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Paracetamol
:Paracetamol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BE01" ;
             rdfs:label "paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Pramod_Kumar_Adusumilli
:Pramod_Kumar_Adusumilli rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "the National Coordination Centre for Pharmacovigilance Programme of India" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Pramod" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Kumar Adusumilli" ;
                         rdfs:label "Pramod Kumar Adusumilli" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Pruritus
:Pruritus rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L29" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037087 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Rash
:Rash rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R21" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037844 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Guidelines for the treatment of malaria, second edition. Authors: WHO. Number of pages: 194. Publication date: 2010. Languages: English. ISBN 978-92-4-154792-5 " ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium: Summary of Product Characteristics for Riamet®. Available from: http://www.medicines.org.uk/emc/medicine/91 96. Accessed: September 2017. " ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Mayo Clinic. Stevens-Johnson syndrome. Available from: http://www.mayoclinic.org/diseasesconditions/stevens-johnsonsyndrome/home/ovc-20317097. Accessed: September 2017." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Foster CS, Ba-Abbad R, Letko E, Parrillo SJ. Stevens-Johnson Syndrome. Dec 15, 2016. Available from: http://emedicine.medscape.com/article/11 97450-overview. Accessed: September 2017. " ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6. " ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997;24:726-9. " ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Indian Label: Lumerax Package insert, Ipca Laboratories, 2017. " ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "US Food and Drug Administration: Product label for artemether/lumefantrine (Coartem®) Available from: https://www.accessdata.fda.gov/drugsatfd a_docs/ label/2015/022268s012lbl.pdf. Accessed: September 2017. " ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kiguba R, Karamagi C, Waako P, Ndagije HB, Bird SM. Rare, serious, and comprehensively described suspected adverse drug reactions reported by surveyed healthcare professionals in Uganda. PLoS One. 2015 Apr 23;10(4):e0123974. " ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportWithALUMonotherapyAndFatalOutcome
:ReportWithALUMonotherapyAndFatalOutcome rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsWithALUMonotherapy ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :onset_5 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
                                         rdfs:label "Report with ALU monotherapy and fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportWithALUMonotherapyAndOnset4
:ReportWithALUMonotherapyAndOnset4 rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsWithALUMonotherapy ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :onset_4 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                   rdfs:label "Report with ALU monotherapy and onset 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsFromDemocraticRepublicOfCongo
:ReportsFromDemocraticRepublicOfCongo rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Democratic_Republic_of_the_Congo" ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports from Democratic Republic of Congo" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsFromGhana
:ReportsFromGhana rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Ghana" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Ghana" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsFromIndia
:ReportsFromIndia rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/India" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from India" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsFromKenya
:ReportsFromKenya rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Kenya" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                  rdfs:label "Reports from Kenya" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsFromTanzania
:ReportsFromTanzania rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Tanzania" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                     rdfs:label "Reports from Tanzania" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsFromZambia
:ReportsFromZambia rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Zambia" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                   rdfs:label "Reports from Zambia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithALUMonotherapy
:ReportsWithALUMonotherapy rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :ALU ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                           rdfs:label "Reports with ALU monotherapy" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithALUMonotherapyAndOnset1
:ReportsWithALUMonotherapyAndOnset1 rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsWithALUMonotherapy ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :onset_1 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "Reports with ALU monotherapy and onset 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithALUMonotherapyAndOnset2
:ReportsWithALUMonotherapyAndOnset2 rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsWithALUMonotherapy ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :onset_2 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "Reports with ALU monotherapy and onset 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithALUMonotherapyAndOnset3
:ReportsWithALUMonotherapyAndOnset3 rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :ReportsWithALUMonotherapy ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :onset_3 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "Reports with ALU monotherapy and onset 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithFatalOutcome
:ReportsWithFatalOutcome rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
                         rdfs:label "Reports with fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithNoRecovery
:ReportsWithNoRecovery rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
                       rdfs:label "Reports with no recovery" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithNon-MonotherapyCases
:ReportsWithNon-MonotherapyCases rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                                            :Albendazole ,
                                                                                                            :NSAIDs ,
                                                                                                            :Paracetamol ,
                                                                                                            :ValproicAcid ,
                                                                                                            :carbamazepine ,
                                                                                                            :ceftriaxone ,
                                                                                                            :phenytoin ,
                                                                                                            :triamterene ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 12 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 rdfs:label "Reports with Non-Monotherapy cases" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithPositiveoutcome-recovery
:ReportsWithPositiveoutcome-recovery rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 13 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
                                     rdfs:label "Reports with positive outcome-recovery" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ReportsWithUnknownOutcome
:ReportsWithUnknownOutcome rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
                           rdfs:label "Reports with unknown outcome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_from_France_with_Artemether-TEN
:Reports_from_France_with_Artemether-TEN rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ToxicEpidermalNecrolysis ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :arte ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/France" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                         rdfs:label "Reports from France with Artemether-TEN" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_from_India_with_ALU-TEN
:Reports_from_India_with_ALU-TEN rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ToxicEpidermalNecrolysis ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :ALU ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/India" ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 rdfs:label "Reports from India with ALU-TEN" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_from_Kenya_with_Artemether-SJS
:Reports_from_Kenya_with_Artemether-SJS rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Stevens-JohnsonSyndrome ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :arte ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Kenya" ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "Reports from Kenya with Artemether-SJS" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_in_VigiBase
:Reports_in_VigiBase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In VigiBase, the WHO global database of individual case safety reports, as of March 2017 there were 19 cases of the combination ALU and SJS among 832 reports in total for ALU. The reports originate from Tanzania (7), Ghana (5), India (3), Kenya (2), Democratic Republic of Congo (1) and Zambia (1), and were entered into the database from 2008 onwards. In the 19 cases the median age of patients was 29 years, ranging from 2 to 64 years. Eleven of the cases concern males, five females, two reports contain ambiguous gender information and in one report the gender information is missing. Reporters were one patient and 18 health care professionals (HCPs), e.g. physicians, pharmacists and other HCPs. All cases were reported as fulfilling serious criteria, with five explicitly stating the condition to be life threatening and with one having a fatal outcome. At the time of reporting and apart from the patient who died, 13 of the patients had recovered or were recovering, two had not yet recovered and for three the outcome was unknown or not reported. Clinical case histories In most reports the case descriptions are very brief with only limited clinical data. Some merely state the diagnosis SJS while others describe in more detail skin blistering with desquamation and mouth, eye or genital ulcerations. A few cases note a general spreading of the syndrome giving a suspicion they would fulfil the clinical definition of SJS/TEN or TEN. In many reports the full course of ALU appears to have been given although onset of symptoms occurred very rapidly after treatment initiation. One report explicitly mentions a positive malaria test whereas most cases state that the patient was treated for malaria or just states ‘fever’ as the treatment indication without providing further information. None of the reports contain any relevant history of previous use of, or reactions to, this or other drugs. ALU monotherapy cases In seven cases where ALU was the only reported drug, the time to onset (TTO) was reported as the same day in two cases, 1 day in two cases, 3 and 5 days in two other cases and in one case with a fatal outcome where the TTO was unknown, the patient died 10 days after onset. Non-Monotherapy cases In all the 12 cases which mention more than one drug as co-suspect or concomitant, at least one of the co-reported drugs is known to have the ability to cause SJS, e.g. phenytoin, valproic acid, carbamazepine, ceftriaxone, benzthiazine/triamterene, albendazole, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA), carbamazepine and paracetamol. The median TTO of SJS from start of ALU in these cases was 1.5 days (unknown in two cases). In the eight cases with co-reported paracetamol the starting date and hence the TTO (when noted) was the same as for ALU whereas in three cases reporting other co-reported/suspect drugs TTO for these were 3-27 days and one noted as “long term use”. In most paracetamol cases, there was no end date noted, hence it is unknown whether this drug was continued or not." ;
                     rdfs:label "Reports in VigiBase" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_regarding_other_artemisin_class_drugs
:Reports_regarding_other_artemisin_class_drugs rdf:type owl:NamedIndividual ,
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :Artemisinin_and_derivatives ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 14 ;
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                               rdfs:label "Reports regarding other artemisin class drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_related_to_the_use_of_artesunate
:Reports_related_to_the_use_of_artesunate rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_regarding_other_artemisin_class_drugs ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> :artes ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 10 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                          rdfs:label "Reports related to the use of artesunate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_with_HCP_as_reporter
:Reports_with_HCP_as_reporter rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 18 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_reporter_type> "health care professional" ;
                              rdfs:label "Reports with HCP as reporter" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_with_artemisin_class_and_SJS
:Reports_with_artemisin_class_and_SJS rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_regarding_other_artemisin_class_drugs ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Stevens-JohnsonSyndrome ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 10 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports with artemisin class and SJS" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_with_artemisin_class_and_TEN
:Reports_with_artemisin_class_and_TEN rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :Reports_regarding_other_artemisin_class_drugs ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ToxicEpidermalNecrolysis ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports with artemisin class and TEN" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Reports_with_patient_as_reporter
:Reports_with_patient_as_reporter rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_reporter_type> "patient" ;
                                  rdfs:label "Reports with patient as reporter" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Steven-Johnson_syndrome_pathophysiology
:Steven-Johnson_syndrome_pathophysiology rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Stevens-JohnsonSyndrome ,
                                                                                                                  :ToxicEpidermalNecrolysis ;
                                         mp:references :Ref.3 ,
                                                       :Ref.4 ,
                                                       :Ref.5 ,
                                                       :Ref.6 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Stevens-Johnson syndrome (SJS) is a severe mucocutaneous immune reaction, characterized by necrosis and detachment of the epidermis of the skin through apoptosis of keratinocytes.3 Common prodromal symptoms of SJS are flu-like symptoms such as fever, sore throat, headache and fatigue, which may initially be misdiagnosed as an infection and treated as such. Typically, a maculopapular blistering skin rash abruptly arises on the face, torso and may spread to arms, legs and soles. Oral, ocular or genital mucous membranes are affected in a majority of patients. The most common cause of SJS is drugs, including anti-malarials. The condition may also be triggered by malignant disease and infections, and regarding the latter, protozoal infections such as malaria and trichomoniasis have been described as causal factors.4 In a significant proportion of the cases no clear causal factor can be identified. Genetic factors such as being a slow acetylator may predispose to SJS. Stevens-Johnson syndrome and the closely related syndrome of toxic epidermal necrolysis (TEN) are variants of a disease continuum where in SJS skin detachment is <10% of the body surface area; in SJS/TEN overlap the area is 10-30% and in TEN involves detachment of >30% of the body surface.5,6 Onset is described as 1- 30 days after start of instigating factor." ;
                                         rdfs:label "Steven-Johnson syndrome pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Stevens-JohnsonSyndrome
:Stevens-JohnsonSyndrome rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L51.1" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10042033 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Stevens-Johnson syndrome" ;
                         rdfs:label "stevens-Johnson syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Summary
:Summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A signal was detected on the serious cutaneous adverse drug reaction (ADR) Stevens-Johnson syndrome (SJS) in relation to the anti-malarial fixed drug combination Artemether/Lumefantrine (ALU) during a signal detection screening focused on reporting patterns in Africa, Asia and Latin America. In the WHO global database of individual case safety reports, VigiBase, as of March 2017 there were 19 reports on this drug-ADR combination. Most reported cases contain relatively little information, the time to onset is somewhat atypical and alternative explanations may have contributed. As other cutaneous reaction terms describing conditions with a clinical closeness to SJS are included in labelling for ALU in parts of the world, this, along with the seriousness of the reaction, is the reason to signal the combination to raise awareness of this issue." ;
         rdfs:label "Summary" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Survey_in_Uganda
:Survey_in_Uganda rdf:type owl:NamedIndividual ,
                           <http://purl.obolibrary.org/obo/OAE_0001197> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
                  mp:references :Ref.9 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In an article describing an ADR reporting survey performed in Uganda one case is described as reported from a doctor where a “52 year old female on Coartem oral route developed sores on the whole body”. No further information is available on the case which can be suspected of describing SJS or TEN.9" ;
                  rdfs:label "Survey in Uganda" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ToxicEpidermalNecrolysis
:ToxicEpidermalNecrolysis rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L51.2" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10044223 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Toxic epidermal necrolysis" ;
                          rdfs:label "toxic epidermal necrolysis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#US_labelling
:US_labelling rdf:type owl:NamedIndividual ,
                       <http://purl.obolibrary.org/obo/OAE_0001197> ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :bullousEruption ,
                                                                                       :hypersensitivity ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
              mp:references :Ref.8 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """The United States Food and Drug Administration (US FDA) label (Coartem®) mentions the following regarding the post marketing experience: “hypersensitivity reactions: like […] serious skin reactions (bullous eruption) have been reported”. This could evidently encompass SJS while SJS is not included per se in the labelling.8
The US labelling mentions serious skin reactions (bullous eruption) in the post marketing experience.8""" ;
              rdfs:label "US labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Uppsala_Monitoring_Centre
:Uppsala_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/ns/prov#Organization> ;
                           rdfs:label "Uppsala Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Urticaria
:Urticaria rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L50" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10046735 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Urticaria" ;
           rdfs:label "urticaria" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ValproicAcid
:ValproicAcid rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AG01" ;
              rdfs:label "valproic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#arte
:arte rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#hasClass> :Artemisinin_and_derivatives ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "P01BE02" ;
      rdfs:label "artemether" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#artes
:artes rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#hasClass> :Artemisinin_and_derivatives ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "P01BE03" ;
       rdfs:label "artesunate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#bullousEruption
:bullousEruption rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L13.9" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006559 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Bullous eruption" ;
                 rdfs:label "bullous eruption" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#carbamazepine
:carbamazepine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AF01 " ;
               rdfs:label "carbamazepine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#ceftriaxone
:ceftriaxone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DD04 " ;
             rdfs:label "ceftriaxone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#conclusion
:conclusion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The US labelling mentions serious bullous skin reactions which could potentially include cases of SJS. The VigiBase case series gives some suspicion of a causal association between ALU and SJS albeit some arguments against such an association are also present within it. While a firm conclusion on causality cannot be drawn at this point, national centres in malaria endemic areas should be aware of this potential issue, monitor and be prepared to take precautionary steps nationally if considered necessary." ;
            rdfs:label "conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#evidence_against_causality
:evidence_against_causality rdf:type owl:NamedIndividual ,
                                     <http://purl.obolibrary.org/obo/OAE_0001182> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "An early stage SJS caused by another factor could be mistaken for malaria and treated as such or the malarial disease could be causing the SJS. The short TTO of 0-2 days in most of the reported cases is somewhat atypical and does weaken the suspicion of a causal association between the drug and the reaction while not excluding it. The insidious start of SJS further makes an exact onset of the condition difficult to establish. There is limited information in the described cases on their respective diagnostic certainty of malaria. The presence of paracetamol, NSAIDs or ASA as concomitant treatment in malaria or SJS would be expected but obviously also obscures any causality assessment. Since case descriptions and information are sparse, other potential but unaccounted-for causes of the SJS appearing within a reasonable timeframe are not possible to rule out, e.g. other infections and other drugs or traditional remedies used" ;
                            rdfs:label "evidence against causality" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#hypersensitivity
:hypersensitivity rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T78.4" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020751 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypersensitivity" ;
                  rdfs:label "hypersensitivity " .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ,
                            :Ref.3 ,
                            :Ref.4 ,
                            :Ref.5 ,
                            :Ref.6 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Fixed-dose combinations of Artemether/Lumefantrine (ALU) are available globally and recommended as one of the first line treatments of uncomplicated malaria (Pl. Falciparum) in infants, children and adults.1 The combination is neither indicated for severe malaria nor for prevention of malaria. A typical treatment course would be six doses consisting of 1-4 tablets per dose over three days.2 Stevens-Johnson syndrome (SJS) is a severe mucocutaneous immune reaction, characterized by necrosis and detachment of the epidermis of the skin through apoptosis of keratinocytes.3 Common prodromal symptoms of SJS are flu-like symptoms such as fever, sore throat, headache and fatigue, which may initially be misdiagnosed as an infection and treated as such. Typically, a maculopapular blistering skin rash abruptly arises on the face, torso and may spread to arms, legs and soles. Oral, ocular or genital mucous membranes are affected in a majority of patients. The most common cause of SJS is drugs, including anti-malarials. The condition may also be triggered by malignant disease and infections, and regarding the latter, protozoal infections such as malaria and trichomoniasis have been described as causal factors.4 In a significant proportion of the cases no clear causal factor can be identified. Genetic factors such as being a slow acetylator may predispose to SJS. Stevens-Johnson syndrome and the closely related syndrome of toxic epidermal necrolysis (TEN) are variants of a disease continuum where in SJS skin detachment is <10% of the body surface area; in SJS/TEN overlap the area is 10-30% and in TEN involves detachment of >30% of the body surface.5,6 Onset is described as 1- 30 days after start of instigating factor." ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#onset_1
:onset_1 rdf:type owl:NamedIndividual ,
                  <http://www.w3.org/2006/time#DurationDescription> ;
         <http://www.w3.org/2006/time#nominalPosition> "hours" ;
         <http://www.w3.org/2006/time#numericPosition> 12 ;
         rdfs:label "onset 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#onset_2
:onset_2 rdf:type owl:NamedIndividual ,
                  <http://www.w3.org/2006/time#DurationDescription> ;
         <http://www.w3.org/2006/time#nominalPosition> "days" ;
         <http://www.w3.org/2006/time#numericPosition> 1 ;
         rdfs:label "onset 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#onset_3
:onset_3 rdf:type owl:NamedIndividual ,
                  <http://www.w3.org/2006/time#DurationDescription> ;
         <http://www.w3.org/2006/time#nominalPosition> "days" ;
         <http://www.w3.org/2006/time#numericPosition> 3 ;
         rdfs:label "onset 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#onset_4
:onset_4 rdf:type owl:NamedIndividual ,
                  <http://www.w3.org/2006/time#DurationDescription> ;
         <http://www.w3.org/2006/time#nominalPosition> "days" ;
         <http://www.w3.org/2006/time#numericPosition> 5 ;
         rdfs:label "onset 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#onset_5
:onset_5 rdf:type owl:NamedIndividual ,
                  <http://www.w3.org/2006/time#DurationDescription> ;
         <http://www.w3.org/2006/time#nominalPosition> "days" ;
         <http://www.w3.org/2006/time#numericPosition> 10 ;
         rdfs:label "onset 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#phenytoin
:phenytoin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AB02" ;
           rdfs:label "phenytoin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#probable_mechanism_of_sjs
:probable_mechanism_of_sjs rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                           mp:references :Ref.4 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The most common cause of SJS is drugs, including anti-malarials. The condition may also be triggered by malignant disease and infections, and regarding the latter, protozoal infections such as malaria and trichomoniasis have been described as causal factors.4 In a significant proportion of the cases no clear causal factor can be identified. Genetic factors such as being a slow acetylator may predispose to SJS." ;
                           rdfs:label "probable mechanism of sjs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Acknowledment ,
                                                                                      :Addendum_regarding_similar_anti-malaria__drugs ,
                                                                                      :Reports_in_VigiBase ,
                                                                                      :Steven-Johnson_syndrome_pathophysiology ,
                                                                                      :Summary ,
                                                                                      :conclusion ,
                                                                                      :introduction ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :OverallReportsInVigibase ,
                                                                                             :ReportWithALUMonotherapyAndFatalOutcome ,
                                                                                             :ReportWithALUMonotherapyAndOnset4 ,
                                                                                             :ReportsFromDemocraticRepublicOfCongo ,
                                                                                             :ReportsFromGhana ,
                                                                                             :ReportsFromIndia ,
                                                                                             :ReportsFromKenya ,
                                                                                             :ReportsFromTanzania ,
                                                                                             :ReportsFromZambia ,
                                                                                             :ReportsWithALUMonotherapy ,
                                                                                             :ReportsWithALUMonotherapyAndOnset1 ,
                                                                                             :ReportsWithALUMonotherapyAndOnset2 ,
                                                                                             :ReportsWithALUMonotherapyAndOnset3 ,
                                                                                             :ReportsWithFatalOutcome ,
                                                                                             :ReportsWithNoRecovery ,
                                                                                             :ReportsWithNon-MonotherapyCases ,
                                                                                             :ReportsWithPositiveoutcome-recovery ,
                                                                                             :ReportsWithUnknownOutcome ,
                                                                                             :Reports_from_France_with_Artemether-TEN ,
                                                                                             :Reports_from_India_with_ALU-TEN ,
                                                                                             :Reports_from_Kenya_with_Artemether-SJS ,
                                                                                             :Reports_regarding_other_artemisin_class_drugs ,
                                                                                             :Reports_related_to_the_use_of_artesunate ,
                                                                                             :Reports_with_HCP_as_reporter ,
                                                                                             :Reports_with_artemisin_class_and_SJS ,
                                                                                             :Reports_with_artemisin_class_and_TEN ,
                                                                                             :Reports_with_patient_as_reporter ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Stevens-JohnsonSyndrome ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
          mp:supportedByData :Indian_labelling ,
                             :Survey_in_Uganda ,
                             :US_labelling ,
                             :evidence_against_causality ,
                             <http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#United_Kingdom,_Australian_and_Swiss_labelling> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "01/04/2018" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#triamterene
:triamterene rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03DB02" ;
             rdfs:label "triamterene" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Artemether/Lumefantrine_and_Stevens-Johnson_syndrome:_a_recommendation_for_continued_vigilance_in_malaria-endemic_areas
<http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#Artemether/Lumefantrine_and_Stevens-Johnson_syndrome:_a_recommendation_for_continued_vigilance_in_malaria-endemic_areas> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Dr_Birgitta_Grundmark ,
                                                                                                                                                                                                                                                                                            :Pramod_Kumar_Adusumilli ;
                                                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :pvSignal ;
                                                                                                                                                                                                                           mp:publishedBy :Uppsala_Monitoring_Centre ;
                                                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/04/2018"^^xsd:date ;
                                                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "Further investigation needed" ;
                                                                                                                                                                                                                           rdfs:label "Artemether/Lumefantrine and Stevens-Johnson syndrome: a recommendation for continued vigilance in malaria-endemic areas" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#United_Kingdom,_Australian_and_Swiss_labelling
<http://purl.org/OpenPVSignal/Signals/2018_3_artemether_lumefantrine_Stevens-Johnson_syndrome.owl#United_Kingdom,_Australian_and_Swiss_labelling> rdf:type owl:NamedIndividual ,
                                                                                                                                                           <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Angioedema ,
                                                                                                                                                                                                                           :FaceEdema ,
                                                                                                                                                                                                                           :Rash ,
                                                                                                                                                                                                                           :Urticaria ,
                                                                                                                                                                                                                           :hypersensitivity ;
                                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :ALU ;
                                                                                                                                                  mp:references :Ref.2 ;
                                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "United Kingdom, Australian and Swiss labels (Riamet®) are very similar and include as acknowledged adverse reactions of the drug combination: rash, urticaria and hypersensitivity, the latter without any further specification.2 Angioedema and face edema are mentioned as reported from post marketing experience." ;
                                                                                                                                                  rdfs:label "United Kingdom, Australian and Swiss labelling" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
